Moreover, the proliferation of IL-17-producing ILC3s induced by NLRP3 activation in the lungs was suggested to directly drive airway hyperresponsiveness, which was ameliorated by the blockade of IL-1β49. The gene discussed is NLRP3; the disease is airway hyperresponsiveness.